BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:05 PM
 | 
Apr 28, 2009
 |  BC Extra  |  Clinical News

Merck reports HCV data

Merck & Co. Inc. (NYSE:MRK) said data from a double-blind Phase IIa trial in 95 patients showed that MK-7009 plus Pegasys peginterferon alfa-2a and ribavirin met the primary endpoint...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >